Clinicopathological and prognostic significance of miR-4317 expression in gastric cancer patients.
Previous studies have revealed that miR-4317 was abnormally expressed and functioned as a tumor suppressor in several tumors, including gastric cancer (GC). However, the clinical significance of miR-4317 in GC remains largely unclear. Our present study aimed at investigating the possibility of miR-4317 as a novel prognostic biomarker for GC patients. RT-PCR was performed to determine the levels of miR-4317 in GC tissues and matched normal gastric tissues. Association between miR-4317 levels and clinicopathological factors was also analyzed using Chi-square test. Kaplan-Meier survival analysis and univariate and multivariate assays were further conducted to investigate the correlation between miR-4317 expression and GC patients prognosis. We showed that miR-4317 expression levels were significantly lower in GC cell lines compared to matched normal tissues (p< 0.01). Down-regulation of miR-4317 was observed to be associated with lymph node metastasis (p = 0.019), distant metastasis (p = 0.011) and TNM stage (p = 0.007). In addition, Kaplan-Meier analysis showed that patients with low miR-4317 expression had a shorter overall survival compared with the high miR-4317 expression group (p = 0.0009). Furthermore, multivariate analysis revealed that miR-4317 expression was an independent prognostic marker of overall survival of GC patients. miR-4317 expression may be a novel and valuable prognostic factor in GC.